Does Stopping Tirzepatide Suddenly Affect Uric Acid Levels?
Yes, abruptly stopping tirzepatide will likely result in a rebound increase in serum uric acid levels, as the uric acid-lowering effect of tirzepatide is primarily mediated by weight loss, which reverses upon discontinuation.
Understanding the Mechanism
Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces serum uric acid (SUA) levels during active treatment. In the SURMOUNT-1 trial analysis, tirzepatide decreased SUA by 0.69-0.95 mg/dL (depending on dose) compared to placebo over 72 weeks, with weight reduction explaining approximately 72.7% of this SUA reduction 1. This means the uric acid-lowering effect is not a direct pharmacologic action but rather a consequence of the substantial weight loss achieved (up to 20.9% body weight reduction) 1.
What Happens Upon Discontinuation
When tirzepatide is stopped abruptly:
- Weight regain is common: Real-world data shows that following discontinuation, patients experience weight regain, with mean body weight change of +1.9% at 12 months post-discontinuation 2
- Metabolic deterioration occurs: Discontinuation leads to deterioration of multiple cardiometabolic risk factors 3
- SUA levels likely rise: Since 72.7% of the SUA reduction is mediated by weight loss 1, the reversal of weight loss upon stopping tirzepatide would be expected to cause SUA levels to return toward baseline
Clinical Implications
The magnitude of SUA rebound depends on whether weight loss is maintained:
- If patients transition to alternative obesity medications (as occurred in 81.9% of patients in one real-world study 2), weight maintenance may preserve some of the uric acid-lowering benefit
- Without alternative weight management strategies, expect SUA to rise proportionally to weight regain
- This is particularly relevant for patients with gout or hyperuricemia who were benefiting from tirzepatide's weight-loss effects
Key Caveats
Tirzepatide is not a urate-lowering therapy in the traditional sense (like allopurinol or febuxostat). The SUA reduction is an indirect benefit of weight loss 1. Therefore:
- Patients with gout should not rely on tirzepatide alone for uric acid management
- If tirzepatide must be discontinued in a patient with gout, consider initiating or optimizing dedicated urate-lowering therapy (xanthine oxidase inhibitors as first-line 4)
- The most common reason for tirzepatide discontinuation in real-world practice is medication cost (80.7% of cases 2), making this a predictable clinical scenario
Bottom line: Abrupt tirzepatide discontinuation will reverse its uric acid-lowering effects as weight is regained, necessitating either transition to alternative weight management strategies or initiation of dedicated urate-lowering therapy in at-risk patients.